Premium
New responsibilities for aged kinases in B‐lymphomas
Author(s) -
Piazza Francesco,
Manni Sabrina,
Arjomand Arash,
Visentin Andrea,
Trentin Livio,
Semenzato Gianpietro
Publication year - 2020
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2694
Subject(s) - cancer research , syk , bruton's tyrosine kinase , casein kinase 1 , kinase , lymphoma , leukemia , chronic lymphocytic leukemia , pi3k/akt/mtor pathway , signal transduction , biology , medicine , tyrosine kinase , immunology , microbiology and biotechnology , protein kinase a
The knowledge accumulated over the last decade on B‐cell–derived non‐Hodgkin lymphoma (B‐NHL) pathogenesis has led to the identification of several molecular abnormalities, opening new perspectives in the design of novel therapies. Indeed, drugs targeting specific biochemical pathways critical for B‐NHL cell survival, proliferation, and fitness within the malignant microenvironment are now available to the clinician: the B‐cell receptor signaling inhibitors of BTK, PI3Kδ, ζ, γ, and SYK or the pro‐apoptotic BH3‐mimetics are clear examples of it. Moreover, it is emerging that malignant B‐cell growth is sustained not only by mutations in oncogenes/tumor suppressors but also by the “addiction” to nononcogene (ie, nonstructurally altered) molecules. In this regard, a consistent body of data has established that the Ser/Thr kinases CK1, CK2, and GSK3 are involved in malignant lymphocyte biology and act as pro‐survival and signaling‐boosting molecules, both in precursor and mature B‐cell tumors. Currently, an experimental and clinical groundwork is available, upon which to design CK1‐, CK2‐, and GSK3‐directed antilymphoma/leukemia therapies. In this review, we have examined the main features of CK1, CK2, and GSK3 kinases, summarized the data in B‐NHL supporting them as suitable therapeutic targets, and proposed a perspective on potential future research development.